SCHEMBL1942292

SCHEMBL1942292

CNc1nc(-c2cccc(NC(=O)c3ccc(Cl)nc3)c2)c2cc(OC)c(OC)cc2n1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.76
PDE4B Q07343 1/20 0.76
PDE4C Q08493 1/20 0.76
PDE4D Q08499 1/20 0.76
CTNNB1 P35222 6/20 0.63
TCF7L2 Q9NQB0 6/20 0.63
MAPT P10636 4/20 0.51
KDM4E B2RXH2 3/20 0.51
PPARG P37231 1/20 0.51
NR2E3 Q9Y5X4 1/20 0.51
NCOR2 Q9Y618 1/20 0.51
MEN1 O00255 5/20 0.48
KMT2A Q03164 5/20 0.48
CYP1A2 P05177 2/20 0.48
CYP2C9 P11712 2/20 0.48
CYP2C19 P33261 2/20 0.48
CYP2D6 P10635 1/20 0.48
ALDH1A1 P00352 2/20 0.47
HTT P42858 3/20 0.47
MAPK1 P28482 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1941711 0.91 PDE4A (0.78) PDE4APDE4BPDE4CPDE4DCTNNB1
SCHEMBL1940196 0.89 PDE4A (0.84) PDE4APDE4BPDE4CPDE4DCTNNB1
SCHEMBL1941723 0.88 PDE4A (0.73) PDE4APDE4BPDE4CPDE4DCTNNB1
SCHEMBL1942877 0.88 PDE4A (0.73) PDE4APDE4BPDE4CPDE4DCTNNB1
SCHEMBL1943723 0.88 PDE4A (0.78) PDE4APDE4BPDE4CPDE4DCTNNB1
SCHEMBL1941543 0.88 PDE4A (0.78) PDE4APDE4BPDE4CPDE4DCTNNB1
SCHEMBL1941364 0.87 PDE4A (0.84) PDE4APDE4BPDE4CPDE4DMAPT
SCHEMBL297387 0.87 PDE4A (0.87) PDE4APDE4BPDE4CPDE4DCTNNB1
SCHEMBL1941734 0.86 PDE4A (0.77) PDE4APDE4BPDE4CPDE4DCTNNB1
SCHEMBL296279 0.86 PDE4A (0.86) PDE4APDE4BPDE4CPDE4DCTNNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1052254-B1 NITROGENOUS HETEROCYCLIC DERIVATIVES AND MEDICINE THEREOF EISAI R&D MAN CO LTD (JP) 2011-06-15 EP disclosed
US-6800644-B2 PHOSPHODIESTERASE-4 INHIBITOR, AMINOQUINOLINE OR AMINOISOQUINOLINE DERIVATIVES EISAI CO., LTD. (JP) 2004-10-05 US disclosed
US-20020055516-A1 Nitrogen-containing heterocyclic compounds and medicaments containing the compounds EISAI CO., LTD. 2002-05-09 US disclosed
US-6352989-B1 ENZYME INHIBITORS FOR PHOSPHODIESTERASE EISAI CO., LTD. (JP) 2002-03-05 US disclosed
EP-1052254-A1 NITROGENOUS HETEROCYCLIC DERIVATIVES AND MEDICINE THEREOF Eisai Co., Ltd. (JP) 2000-11-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020055516-A1 Nitrogen-containing heterocyclic compounds and medicaments containing the compounds PDE4A, PDE4B, PDE5A PDE4A 1/4885PDE4B 2/4885PDE4C 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.